Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05472922

The Banded Mini Gastric Bypass Trial: A Prospective Randomized Controlled Trial

Rationale: Investigate if there is a significant weight reduction expressed in total body weight loss percentage (%TBWL) in patients 5 years after surgery, whom underwent a mini gastric bypass (MGB-OAGB) with addition of the implantation of a MiniMizer Ring.

Study design: A prospective non blinded single centre randomized controlled trial.

Sudy population: The study population will exist of patients eligible for MGB-OAGB surgery. Patients are invited to participate if Body Mass Index (BMI) ≥ 35kg/m2 with a comorbidity related to morbid obesity, or a BMI exceeding 40kg/m2.

Intervention: Insertion of the MiniMizer Ring around the gastric pouch in addition to the 'standard' MGB-OAGB.

Main study parameters/endpoints:

Primary Objective:

1. %TBWL 5 years after surgery.

Secondary Objectives: 2. Percentage Excess Weight Loss (%EWL) 5 years after surgery. 3. Decrease or reduction of comorbidities (diabetes mellitus, hypertension, hyperlipidemia, sleep apnoea, and joint complaints). 4. Improvement of quality of life: SF-36 and OBESI-Q questionnaires. 5. Incidence and severity of dumping syndrome. 6. Incidence and severity of reflux symptoms: GERD-HRQoL questionnaire. 7. Incidence and complications due to silicone band.

Measurement of objectives are before surgery and six times after surgery combined with the standard postoperative care for patients who undergo bariatric surgery:

Expected advantages of bOLGB versus OLGB:

1. Increase of weight reduction, and due to that decrease of comorbidities and/or mortality related to overweight. 2. Long term decrease of weight regain. 3. Decrease of incidence of dumping.

Possible disadvantages of bOLGB versus OLGB:

1. Band-related complications such as erosion, infection, stenosis, or pouch dilatation. 2. Functional gastro-intestinal complains such as dysphagia and reflux.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients meet IFSO criteria for Bariatric Surgery
  • Age 18 and above

Exclusion criteria

  • Previous Bariatric surgery
  • Inability to read and understand written information
  • Any genetic condition that can hamper the acceptance of medical advice
  • chronic bowel disease
  • Severe kidney of liver disease
  • Pregnancy at the start or during the research period
  • Patients with pre-existing therapy refractory GERD
  • Patients with an allergy to silicone

Treatment and study plan

Placement of MiniMizer Gastric Ring

Device

Insertion of MiniMizer Gastric Ring in addition to the normal MGB-OAGB

Normal MGB-OAGB

Procedure

No insertion of Minimizer Gastric Ring in addition to the normal MGB-OAGB

Primary outcomes

  1. Total Body Weight Change 5 years after surgery

    Time frame: 5 Years

    Percentage total body weight change 5 years after the procedure

Secondary outcomes

  1. Change in Percentage Excess Weight (%EWL) 5 years after surgery

    Time frame: 5 years

    Change in Percentage Excess Weight (%EWL)

  2. Change in (existing) co-morbidities 5 years after surgery

    Time frame: 5 years

    Change in severity of obesity-related co-morbidities: Type 2 Diabetes Mellitus (changes in HbA1c or use of antidiabetic medication), Hypertension (changes in bloodpressure or changes in use of antihypertensives), Osteo-arthritis (changes in VAS-score or use of analgesia drugs) , Hyperlipidemia (changes in HDL/LDL ratio, triglycerides or use of statine drugs), Obstructive Sleep Apnea syndrome (changes in use of CPEP treatment or changes is apneu hypopneu idex), and Gastro-Esophageal Reflux Disease (Changes in outcomes of GERD-HR questionnnaire which scoring scale runs from 0 (asymptomatic) to 50 (complete prohibitive) or changes in use of protonpompinhibitors)

  3. Outcome measurement of SF-36 questionnaire

    Time frame: 5 years

    Evalution of changes in outcome of SF-36 Questionnaire 5 years after surgery. Scoring scale is described between 0 (lowest) and 100 (highest) to evaluate patient's welfare

  4. Outcome measurement of OBESI-Q questionnaire

    Time frame: 5 years

    Evalution of changes in outcome of OBESI-Q Questionnaire 5 years after surgery. Scoring scale is described between 0 (lowest) and 100 (highest) to evaluate patient's welfare

  5. Dumping Syndrome

    Time frame: 5 years

    The presence and severity of complains related to Dumping Syndrome in participants (yes or no)

  6. Complications

    Time frame: 5 years

    The occurrence of short- and long-term complications of the minimizer ring

Study contacts

Contact information is provided by the study sponsor or research team.

Marc J van Det, MD PhD

CONTACT

[email protected]

+31887087878

Maureen Tissink, MD

CONTACT

[email protected]

+31887087878

Sponsors and collaborators

Lead sponsor

Marc van Det

Other

Collaborators

  • Ziekenhuisgroep Twente

Registry information

Acronym: RiMini

Important dates

Study start
2022
Primary completion
2023
Study completion
2028
First posted
Jul 25, 2022
Registry last updated
Jul 25, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.